Studies using targeted gene deletion in mice have revealed distinct roles for individual isozymes of the protein kinase C (PKC) family of enzymes in regulating sensitivity to various drugs of abuse. These changes in drug sensitivity are associated with altered patterns of drug selfadministration. The purpose of this review is to summarize behavioral studies conducted on mice carrying targeted deletions of genes encoding specific PKC isozymes (namely the b, c, d, and e isozymes), and to critically evaluate the possibility of using pharmacological inhibitors of specific PKC isozymes as modulators of the sensitivity to various drugs of abuse, as well as potential aids in the treatment of substance use disorders.
Introduction
The protein kinase C (PKC) family of phospholipiddependent kinases comprises nine genes encoding at least 10 distinct members that are structurally related and transduce signals involving lipid second messengers (Nishizuka, 1988) . The 10 PKC isozymes are typically divided into subcategories according to their structure, calcium dependence, and lipid activators. The conventional PKCs (a, bI, bII, and g) are activated by calcium and the lipid signaling intermediate diacylglycerol (DAG) . Novel PKCs (d, e, Z, and y) are activated by DAG but not calcium. Atypical PKCs (B, and l/i) require neither DAG nor calcium, but are instead activated by lipids such as phosphatidic and arachidonic acid (Hirai and Chida, 2003) . PKCl and PKCi are the respective human and mouse homologs of the same enzyme. Additional kinases related to the PKC family are the PKC-related kinases PRK1 and PRK2, which are insensitive to calcium and DAG, but show increased activity when bound to activated RhoA GTPase (Mellor and Parker, 1998) . Two other enzymes, PKCm and PKCu are activated by DAG but not by calcium, similar to novel PKCs. However, these enzymes contain additional functional domains and display a different pattern of substrate specificity, and have now been classified separately as members of the protein kinase D family (Rykx et al., 2003) .
With the exception of PKCy, all PKC isozymes are expressed in the brain to varying degrees, and often the degree of expression can vary with developmental stage. Many PKC isozymes are expressed in both neurons and glia.
For the precise neuroanatomical localization of individual PKC isozyme, the reader is directed to other published studies for more detailed information (Huang et al., 1988; Young, 1988; Tanaka and Saito, 1992; Naik et al., 2000; Minami et al., 2001) . In this review, we will summarize studies that have used targeted deletions of genes encoding specific PKC isozymes to examine their role in regulating the behavioral and biochemical sensitivity to drugs of abuse, and drug self-administration.
Role of individual protein kinase C isozymes in sensitivity to drugs of abuse
Exposure of experimental animals to drugs of abuse such as ethanol, opiates, and psychostimulants can alter the expression or subcellular localization of various PKC isozymes (reviewed in Olive and Messing, 2004; Newton and Messing, 2006; Newton and Ron, 2007; Lee and Messing, 2008) . Behavioral experiments using nonspecific PKC inhibitors have suggested roles for this family of enzymes in regulating the behavioral responses to drugs of abuse. For example, nonspecific PKC inhibitors can reduce the locomotor effects of psychostimulants (Browman et al., 1998; Narita et al., 2004) . However, because of the high degree of structural homology between individual PKC isozymes, particularly in the kinase domain, small molecule activators or inhibitors of specific PKC isozymes have been extremely difficult to develop. As a result, researchers have frequently used targeted gene disruption and other genetic techniques to determine the precise role of PKC isoforms in addictionrelated behaviors (Choi and Messing, 2003; Olive and Ron, 2003 ) (see Table 1 ).
PKCb
PKCb is a conventional PKC isoform whose gene is subject to alternative splicing to form two variants, PKCbI and PKCbII. This isozyme has well-established roles in immune system function and insulin signaling (Kawakami et al., 2002) . However, there is some evidence that it is also involved in behavioral and neurochemical responses to abused drugs. For example, amphetaminestimulated dopamine efflux in the ventral forebrain is blocked by the PKCb inhibitor, LY379196 (Johnson et al., 2005) , a compound that has a high degree of specificity for this isozyme (Jirousek et al., 1996) . The behavioral significance of this observation was revealed by experiments using PKCb-null mice, which showed significantly reduced locomotor stimulation after acute amphetamine treatment (3 mg/kg) (Chen et al., 2009) . Molecular experiments by the same authors revealed that PKCb is essential for normal and amphetamine-induced alterations in trafficking of the dopamine transporter (Chen et al., 2009) , providing a possible mechanistic explanation for their behavioral observations. We are not aware of experiments examining the sensitivity of PKCb-null mice to other drugs of abuse.
PKCc
PKCg is expressed exclusively in the central nervous system, and mice carrying a targeted deletion of the gene encoding PKCg were generated in the early 1990s to examine its role in long-term potentiation and learning and memory processes (Abeliovich et al., 1993a (Abeliovich et al., , 1993b . Subsequently, the behavioral and biochemical effects of ethanol were examined in these mice (Harris et al., 1995) . Electrophysiological measurements showed that cortical microsacs from these mice were insensitive to the ability of low concentrations (15 mmol/l) of ethanol to potentiate the function of the g-aminobutyric acid (GABA A ) receptor as measured by 36 Clinflux. In slice preparations of the hippocampal CA1 region, the ability of 80 mmol/l ethanol to potentiate GABA A receptormediated inhibitory postsynaptic currents was absent in PKCg-deficient mice (Proctor et al., 2003) . This reduced sensitivity to the effects of ethanol on GABA A receptor function was demonstrated behaviorally; PKCg-deficient mice had reduced hypnotic and hypothermic responses to high doses (3.5 g/kg) of peripherally administered ethanol (Harris et al., 1995) . Subsequently, it was shown that repeated exposure of PKCg-deficient mice to ethanol (either by liquid diet consumption or repeated intraperitoneal injections) failed to result in tolerance to the hypnotic and hypothermic effects of high doses of ethanol, although this effect was dependent on the genetic background of the mice used (Bowers et al., 1999 (Bowers et al., , 2000 . In the aforementioned studies, behavioral and electrophysiological responses to benzodiazepines were unchanged in PKCg-null mice. Thus, these studies suggest that PKCg plays a critical role in regulating behavioral sensitivity to ethanol, and the ability of ethanol to potentiate GABA A receptor function, but this may not be a general function of GABA A receptor modulation by PKCg. The a1 and a4 subunits of GABA A receptors have been found to co-immunoprecipitate with PKCg from the rat cerebral cortex (Kumar et al., 2002) ; however, direct phosphorylation of these subunits by PKCg has not, to our knowledge, been shown.
With regard to other drugs of abuse, studies conducted on PKCg-deficient mice have shown a role for PKCg in regulating sensitivity to opiates. For example, deletion of PKCg results in increased m-opioid receptor binding in the spinal cord (Narita et al., 2001b) , and increased m-opioid stimulated G-protein signaling in the lower brainstem (Narita et al., 2001c) . These findings suggest a molecular basis for the enhanced m-opioid receptor-mediated analgesia that is found in PKCg-deficient mice (Narita et al., 2001c; Celerier et al., 2004) . Despite the increased sensitivity of PKCg-deficient mice to the analgesic effects of m-opioid receptor agonists, these mice failed to show a conditioned place preference to a 5 mg/kg subcutaneous dose of morphine (Narita et al., 2001a) . One possible interpretation of these seemingly counterintuitive findings is that the function of m-opioid receptors expressed in brain regions that mediate the rewarding effects of morphine may not regulated by PKCg in the same manner as in brain regions that mediate m-opioid-induced analgesia. Alternatively, as PKCg-deficient mice show deficits in contextual learning (Abeliovich et al., 1993b) , it is possible that these mice have an impaired ability to associate the subjective rewarding effects of morphine with the environmental context in which it was administered, thereby rendering them unable to express a conditioned place preference. Further studies on the precise mechanisms and brain regions where PKCg regulates m-opioid receptor function are needed to clarify this, as are experiments to determine if PKCg-deficient mice are capable of establishing a conditioned place preference to other conditioned appetitive stimuli.
PKCd
Exposure of PC12 cells to ethanol increases the expression of PKCd (Messing et al., 1991) . To our knowledge, only one study has been conducted examining the effect of targeted deletion of the gene encoding PKCd on sensitivity to ethanol. Choi et al. (2008) showed that mice carrying a null mutation for the PKCd gene displayed a marked resistance to the ataxic effects of ethanol (1.5-2 g/kg intraperitoneal) as assessed on a rotarod. Sensitivity to the hypothermic and hypnotic effects of ethanol was also reduced. The ataxic effects of the general GABA A receptor potentiators pentobarbital and pregnanolone were also reduced, but ataxic responses to the benzodiazepine flunitrazepam were normal (Choi et al., 2008) . As flunitrazepam acts only at GABA A receptors containing the g 2 subunit, these data suggested that PKCd may regulate ethanol potentiation of GABA A receptors that do not contain this subunit, the most abundant of which are extrasynaptic, contain the d subunit, and regulate tonic inhibition of neurons. In this same study, electrophysiological experiments in brain slices revealed that ethanol potentiated these tonic currents in neurons located in the thalamus and hippocampus, both of which are brain regions implicated in ataxia. However, this potentiation of tonic GABA-mediated currents was not found in PKCdnull mice, suggesting that PKCd regulation of GABA A receptors containing the d subunit may contribute to ethanol-induced ataxia. In the same study, the authors found that the ataxic effects of ketamine were normal in PKCd-null mice, but to our knowledge, the sensitivity of PKCd-null mice to psychostimulants, opiates, nicotine, and other abused substances has not yet been examined.
PKCe
Numerous studies have implicated PKCe in regulating sensitivity to various drugs of abuse. PKCe-deficient mice were first generated in the late 1990s and showed a role for this isozyme in nociception (Khasar et al., 1999) . Not long after the initial characterization of these mice, Hodge et al. showed that PKCe-deficient mice displayed supersensitivity to the behavioral and biochemical effects of ethanol and other positive allosteric modulators of the GABA A receptor (Hodge et al., 1999 (Hodge et al., , 2002 . PKCedeficient mice lacked any evidence for compensatory upregulation of other PKC isozymes as measured by western blot analysis.
Crude synaptosomes (microsacs) isolated from the frontal cortex of wildtype and PKCe-deficient mice showed similar GABA A receptor responsiveness (as measured by 36 Cluptake) to orthosteric agonists such as muscimol. However, the addition of allosteric potentiators of GABA A receptor function, such as ethanol, benzodiazepines, barbiturates, and GABAergic neurosteroids dramatically increased 36 Cluptake in tissue from PKCe-deficient mice (Hodge et al., 1999 (Hodge et al., , 2002 . The enhanced GABA A receptor sensitivity was reproduced in microsacs from wildtype mice after preincubation with the PKCe translocation inhibitor peptide eV1-2, which had no effect on 36 Cluptake in microsacs from PKCe-deficient mice, verifying that the enhanced GABA A receptor sensitivity was indeed a result of loss of PKCe. Using slice electrophysiology, it was later shown that ethanol (80 mmol/l) enhanced GABA A receptor-mediated inhibitory postsynaptic currents in the CA1 region of the hippocampus of PKCe-null mice, but not wildtype littermates (Proctor et al., 2003) . This enhanced sensitivity of GABA A receptors to positive allosteric modulators such as ethanol, benzodiazepines, barbiturates, and GABAergic neurosteroids in PKCe-deficient mice was paralleled by behavioral supersensitivity to these drugs. For example, PKCe-null mice showed prolonged hypnotic effects of high doses of ethanol and benzodiazepines as measured by the loss-of-righting reflex, and increased locomotor stimulant effects of lower doses of ethanol (Hodge et al., 1999 (Hodge et al., , 2002 . Locomotor responses to the N-methyl-D-aspartic acid receptor antagonist MK-801 did not differ between PKCe-deficient and wildtype mice, suggesting normal functioning of N-methyl-D-aspartic acid receptors in these mice. Other behavioral indices of increased GABA A receptor sensitivity and/or functioning in PKCe-deficient mice have been manifested by reduced anxiety-like behaviors (Hodge et al., 2002) , reduced ethanol withdrawal severity (Olive et al., 2001) , and reduced acute functional tolerance to the ataxic effects of ethanol .
Since the discovery of the opposing altered biochemical and behavioral supersensitivity to ethanol in PKCg and PKCe-deficient mice, it has been hypothesized that the resulting phenotypes of these mice are a result of an altered phosphorylated state of the GABA A receptor, as there is substantial evidence that PKC regulates GABA A receptor function (Song and Messing, 2005 ). This hypothesis was tested by Qi et al. (2007) who showed that PKCe directly phosphorylates the serine 327 residue of the g 2 subunit of the GABA A receptor, and that limiting this phosphorylation produced an enhanced electrophysiological sensitivity of these receptors to ethanol and benzodiazepines. Other possible mechanisms by which responsiveness to ethanol and other allosteric modulators of GABA A receptor function is altered by PKC isozymes include regulation of GABA A receptor cell surface expression, intracellular trafficking, and degradation (Song and Messing, 2005) . In addition, PKCe-null mice have increased extracellular levels of endogenous taurine (Olive et al., 2000) , a sulfonated amino acid that potentiates GABA A receptor function.
PKCe also seems to mediate the ability of ethanol to potentiate glycine receptor function. Jiang and Ye (2003) showed that the PKCe peptide translocation inhibitor eV1-2 actually decreased the ability of low concentrations of ethanol (10 mmol/l) to potentiate glycine receptor function in slices of the ventral tegmental area. These findings are of interest, as GABA A and glycine are both ligand-gated chloride channels, but their function seems to be regulated by PKCe in opposite manner. In addition, PKCe regulation of glycine receptor responses to ethanol may represent a non-GABAergic mechanism by which this isozyme regulates ethanol sensitivity.
In addition to regulating sensitivity to abused substances that target the GABA A receptor (i.e. ethanol, benzodiazepines, and barbiturates) or glycine receptors (i.e. ethanol), recent studies have shown that PKCe also regulates behavioral and biochemical sensitivity to opiates and cannabinoids. For instance, PKCe-deficient mice are supersensitive to the rewarding, reinforcing, and supraspinal analgesic effects of morphine . However, the mechanisms underlying these observations are unclear, as this study showed that brain m-opioid receptor densities and G-protein coupling are unaltered in PKCe-deficient mice. PKCe-deficient mice also display supersensitivity to the analgesic and hypothermic effects of the cannabinoid receptor 1 (CB 1 ) agonist WIN55,212-2, but not the structurally unrelated CB 1 agonist CP55,940 . Tolerance to the behavioral effects of WIN55,212-2 was also enhanced in PKCe-deficient mice. These latter behavioral findings were paralleled by evidence of increased CB 1 receptor binding affinity. Thus, in addition to the GABA A receptor, PKCe also seems to regulate sensitivity to m-opioid and cannabinoid agonists; however, further studies are needed to determine whether these observations are a result of direct interaction of PKCe with m-opioid or CB 1 receptors.
Role of individual protein kinase C isozymes in self-administration of drugs of abuse PKCa
Postmortem analysis of brains from heroin addicts has shown a reduction in the level of PKCa expression (Busquets et al., 1995; Garcia-Sevilla et al., 1997) , indicating that the expression level of at least one PKC isozyme is altered in human addicts. In addition, a microarray study showed reduced PKCa expression in the nucleus accumbens of rats, which had been trained to self-administer ethanol (Rodd et al., 2008) . However despite these intriguing genetic findings we are not aware of any behavioral studies examining the effects of PKCa knockdown or knockout on the self-administration of, or sensitivity to, drugs of abuse.
PKCb
Despite the reported roles for PKCb in regulation of dopamine transporter trafficking and amphetamine sensitivity mentioned above, self-administration of drug and place preference have not, to our knowledge, been examined in PKCb-null mice or in conjunction with the PKCb-specific inhibitor LY379196. This is perhaps unfortunate, as the inhibition of PKCb would be hypothesized to block the behavioral effects of amphetamines and thus perhaps be a therapeutic strategy for the treatment of psychostimulant addiction.
PKCc
The reduced sensitivity to ethanol exhibited by PKCgdeficient mice is paralleled by increased ethanol consumption in a two-bottle choice paradigm (Bowers and Wehner, 2001) . No differences in saccharin or nicotine consumption were noted, indicating that the effects were specific to ethanol. We are unaware of any studies to date that have examined differences in patterns of selfadministration of opiates, nicotine, or psychostimulants in PKCg-null mice. This is unfortunate, as there is evidence that PKCg-null mice exhibit increased impulsivity in an appetitive nosepoke task (Bowers and Wehner, 2001) , and impulsivity is a behavioral trait associated with risk for developing addiction (Everitt et al., 2008; Crews and Boettiger, 2009 ).
PKCd
Similarly, we are unaware of any studies that have examined differences in voluntary self-administration of psychostimulants, opiates, nicotine, ethanol, or other abused substances in PKCd-deficient mice and wildtype mice. However, such studies are certainly warranted, as inhibition of PKCd function by small interfering RNA knockdown or dominant-negative protein expression in cultured midbrain cells increases the phosphorylation and activity of tyrosine hydroxylase (Zhang et al., 2007) , the rate-limiting enzyme involved in the synthesis of dopamine. The effects of PKCd inhibition are indirect, resulting from a decrease in phosphorylation of PP2A, a phosphatase that dephosphorylates tyrosine hydroxylase thereby reducing its activity. The net result of PKCd inhibition might therefore be expected to be an increase in dopamine levels and this was indeed found in the striatum of PKCd-null mice (Zhang et al., 2007) . These findings are of interest in light of the well-established involvement of mesocorticolimbic dopaminergic transmission in regulating drug reinforcement and incentive learning (Di Chiara et al., 2004; Wise, 2004; Koob and Volkow, 2010) .
PKCe
In a two-bottle choice paradigm, PKCe-deficient mice consumed approximately 75% less alcohol and showed reduced ethanol preference as compared with wildtype mice (Hodge et al., 1999) . PKCe-deficient mice did not differ in their total fluid consumption or intake of saccharin or quinine-containing fluids. Thus, reduced intake was specific for ethanol. Restoration of PKCe expression by means of tetracycline-regulated transgenic 'rescue' increased ethanol intake in PKCe-deficient mice to levels similar to those observed in wildtype mice (Choi et al., 2002) , suggesting that reduced alcohol consumption in PKCe-deficient mice is due to a loss of PKCe Reduced amphetamine-stimulated locomotor activity and ventral forebrain dopamine release g
Reduced behavioral and GABA A receptor sensitivity to ethanol; increased ethanol consumption; increased m-opioid receptor binding and m-mediated analgesia; lack of conditioned place preference to morphine d
Reduced behavioral and GABA A receptor sensitivity to ethanol e Increased behavioral and GABA A receptor sensitivity to ethanol; reduced ethanol withdrawal severity, ethanol-stimulated mesolimbic dopamine release, acute functional tolerance to ethanol, and ethanol consumption; increased behavioral sensitivity to morphine and cannabinoids; self-administration of ultra-low doses of morphine GABA, g-aminobutyric acid.
in adult neurons rather than developmental alteration of other neural substrates underlying the motivation to consume ethanol. In an operant self-administration paradigm, PKCe-deficient mice also showed an approximate 50% reduction in ethanol self-administration, as compared with wildtype mice (Olive et al., 2000) . In this study PKCenull mice also showed a blunted alcohol deprivation effect (i.e. increased ethanol consumption immediately after a period of imposed abstinence). Place preference studies have revealed that PKCe-null mice exhibit an increased sensitivity to the aversive effects of ethanol, but reduced sensitivity to the rewarding effects of ethanol . Recent studies using site-specific inhibition of PKCe function (through small interfering RNA knockdown of PKCe expression or infusion of a cellpenetrant form of eV1-2) have shown the activity of this enzyme in the amygdala, but not nucleus accumbens, mediates ethanol consumption or reinforcement (Gass and Olive, 2009; Lesscher et al., 2009) . A genetic screening study using inbred mouse strains identified higher levels of PKCe expression in strains that show high levels of ethanol expression. This study was conducted on mice which had not been exposed to ethanol, suggesting that PKCe levels are correlated with predisposition to high/low ethanol intake (Mulligan et al., 2006) .
The only study that has explored potential alterations in patterns of intravenous drug self-administration in PKCedeficient mice was conducted by . In this study, wildtype and PKCe-deficient mice were trained to self-administer morphine through the intravenous route, and it was found that PKCe-deficient mice developed morphine self-administration at a low dose (0.1 mg/kg/infusion) that did not generate self-administration behavior in wildtype mice, consistent with the m-opioid supersensitivity phenotype in PKCe-deficient mice . The abundant animal literature about PKCe and drug self-administration/ sensitivity led to its inclusion on a panel of markers for haplotype analysis of addiction-related genes (Hodgkinson et al., 2008) .
Do protein kinase C isozyme modulators have a future in the treatment of addiction?
The evidence presented above suggests that pharmacological manipulation of PKC isozymes may produce beneficial effects in the treatment of addiction. For example, a PKCe inhibitor may reduce alcohol intake while also increasing sensitivity to the analgesic effects of opiates. A PKCb inhibitor may inhibit the acute effects of amphetamine and possibly other psychostimulants while manipulation of PKCd activity might result in alterations in the activity of tyrosine hydroxylase and thus altered dopamine levels. Unfortunately there are no pharmacological compounds that are available and approved for use in humans that target individual PKC isozymes, although peptide reagents that alter the function of PKCd and PKCe are in advanced phases of development for the treatment of cardiac conditions (Yonezawa et al., 2009 ). The PKCb inhibitor, ruboxistaurin (LY333531, from the same chemical class as the aforementioned LY379196) is in advanced clinical trials for the treatment of diabetic retinopathy (Danis and Sheetz, 2009 ), but no studies to date have examined its effects on addiction-related behaviors.
PKC isozymes have functional roles in many biological systems, in addition to the responses to drugs of abuse described here. Indeed, PKCe alone has proposed roles in a wide spectrum of diseases and disorders, including cancer (Basu and Sivaprasad, 2007; Gorin and Pan, 2009 ), cardiac disorders (Churchill et al., 2008) , inflammation (Aksoy et al., 2004) , pain (Khasar et al., 1999) , and anxiety (Hodge et al., 2002; Lesscher et al., 2008) . PKCd has been implicated in many of these systems and is also a key promoter of apoptosis (Reyland, 2007) . These studies suggest that, even when isozyme-specific reagents become available, they will have to be used with care because of the potential for affecting multiple systems.
An additional path to the development of treatments for addiction, using knowledge gained in the studies described in this review, may be to map the signaling pathways in which specific PKC isozymes operate. Each PKC isozyme seems to phosphorylate multiple substrates (e.g. Newton and Messing, 2010) . Manipulating the interaction between a kinase and its substrate may produce more focused effects than systemic manipulation of the kinase alone. For example, regulation of GABA A receptors by PKCs is clearly a mechanism by which these kinases contribute to addictive behaviors. It might be expected that manipulation of PKC-GABA A receptor interactions would produce mostly neurological effects. In addition, the described specificity of PKC isozymes for receptors containing certain GABA A receptor subunits (g 2 -containing receptors for PKCe, d-containing receptors for PKCd) may provide an additional level of control for unwanted effects on multiple biological systems.
